|

TT125-802 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • TOLREMO therapeutics AG1

Indications

  • KRAS G12C1
  • Adult Disease1
  • Adult Solid Tumor1
  • eGFR1
  • Squamous Cell Lung Cancer1

Nashville, Tennessee1 trial

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

Sarah Cannon Research Institute Oncology Partners

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.